AAP
CPRX

Arax Advisory Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Arax Advisory Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.12K Sell
140
-41
-23% -$977 ﹤0.01% 2878
2025
Q4 		$4.22K Buy
+181
New +$4.03K ﹤0.01% 2944
2025
Q1 		– Sell
-349
Closed -$7.28K – 2746
2024
Q4 		$7.28K Sell
349
-7
-2% -$150 ﹤0.01% 1605
2024
Q3 		$7.08K Hold
356
– – ﹤0.01% 1556
2024
Q2 		$5.51K Buy
+356
New +$5.54K ﹤0.01% 1553

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Arax Advisory Partners's CPRX Position: Q1 2026 in Review

Arax Advisory Partners reduced its Catalyst Pharmaceutical (CPRX) stake by 23% in Q1 2026, selling an estimated $977 and leaving 140 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Arax Advisory Partners first reported a position in CPRX in Q2 2024 and has held it in 5 quarters since. The position peaked at $7.28K in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Arax Advisory Partners held 140 shares of Catalyst Pharmaceutical worth $4.12K as of Q1 2026.
  • Arax Advisory Partners sold 41 Catalyst Pharmaceutical shares in Q1 2026, an estimated $977.
  • Catalyst Pharmaceutical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2878 holding.
  • Arax Advisory Partners first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Catalyst Pharmaceutical position peaked at $7.28K in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.